📰 Clinical Development News

Page 56 - Clinical Development News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Clinical Development. Real-time updates on events, politics, business and more.

SOLIRIS Drug Insight and Market Forecasts, 2019-2032: The First Therapy Approved to Treat Patients with PNH

December 8, 2023

/PRNewswire/ -- The "SOLIRIS Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.coms offering. This report provides...

United Kingdom United States Laura Wood Clinical Development Office Hours Call E St Office Hours Call

Source: prnewswire.com

JointStem Emerging Drug Insight and Market Forecasts, 2019-2032: The World's First Stem Cell Therapy for Patients with Severe Knee OA

December 8, 2023

/PRNewswire/ -- The "JointStem Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.coms offering. This report...

South Korea United States United Kingdom Laura Wood E St Office Hours Call Office Hours Call

Source: prnewswire.com

Invossa Emerging Drug Insights and Market Forecasts, 2019-2032: An Allogeneic (donor) Cell and Gene Therapy

December 8, 2023

/PRNewswire/ -- The "Invossa Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.coms offering. This report provides...

United States United Kingdom Kolon Tissuegene Laura Wood E St Office Hours Call Office Hours Call

Source: prnewswire.com

Pozelimab Emerging Drug Insight and Market Forecasts, 2019-2032: An Investigational, Fully Human mAb Designed to Block Complement Factor C5 and Prevent the Destruction of Red Blood Cells

December 8, 2023

/PRNewswire/ -- The "Pozelimab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.coms offering. This report...

United States United Kingdom Laura Wood E St Office Hours Call Office Hours Call Clinical Development

Source: prnewswire.com

APP13007 Emerging Drug Insights and Market Forecasts, 2019-2032: Focus on United States, Germany, France, Italy, Spain, United Kingdom, Canada and South Korea

December 8, 2023

/PRNewswire/ -- The "APP13007 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.coms offering. This report...

United States South Korea United Kingdom Laura Wood Aimmax Therapeutics Inc E St Office Hours Call

Source: prnewswire.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Bertilimumab Emerging Drug Insight and Market Forecasts, 2019-2032: A Fully Human Monoclonal Antibody with Specificity for Human Eotaxin-1 and Inhibits its Function

December 8, 2023

/PRNewswire/ -- The "Bertilimumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.coms offering. This report...

United States United Kingdom Laura Wood Office Hours Call E St Office Hours Call Clinical Development

Source: prnewswire.com

Losmapimod Emerging Drug Insight and Market Forecasts, 2019-2032: An Investigational, Selective p38 Mitogen-Activated Protein Kinase (MAPK) Inhibitor

December 8, 2023

/PRNewswire/ -- The "Losmapimod Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.coms offering. This report...

United States United Kingdom Laura Wood Office Hours Call Clinical Development E St Office Hours Call

Source: prnewswire.com

Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial -December 08, 2023 at 07:30 am EST

December 8, 2023

SAN DIEGO, Dec. 08, 2023 -- Kura Oncology, Inc. , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia...

United States New Zealand Ryan Mcdonald Gwen Nichols Alexandra Weingarten Mollie Leoni

Source: marketscreener.com

Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial

December 8, 2023

SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood cancer research, today announced a clinical collaboration to evaluate Kura’s menin inhibitor, ziftomenib, in combination with chemotherapy in pediatric patients with relapsed/refractory KMT2A-rearra...

New Zealand United States Gwen Nichols Alexandra Weingarten Ryan Mcdonald Mollie Leoni

Source: yahoo.com